https://www.selleckchem.com/pr....oducts/INCB18424.htm
70.6% of female patients and 67.9% of male patients were diagnosed with stage 4 cancer. The prevalence of sarcopenia in the whole patient group was 29.6%. By multivariate analysis, SMI (p=0.009) and advanced stage (p=0.003) were found as poor prognostic factors for overall survival (OS). The neutrophil to lymphocyte ratio (NLR) was statistically significantly higher in sarcopenic patients than in nonsarcopenic patients (p=0.031). Patients having sarcopenia at the time of diagnosis may demonstrate poorer overall survival of pancreatic
Curtir
Comentario
Compartilhar
